Medication treatment prior to index visit.
| Variables | Incident Malignancy, n = 880 |
|---|---|
| Treatment reported at visit prior to index visit of cancer diagnosis*, n | 880 |
| bDMARD | 367 (41.7) |
| TNFi | 286 (32.6) |
| Non-TNFi | 76 (8.5) |
| tsDMARD | 5 (0.6) |
| Not on bDMARD/tsDMARD | 513 (58.3) |
| Prior to index visit, history of no. csDMARD, n | 880 |
| Mean (SD), median (IQR) | 1.1 (1.2), 1 (0–2) |
| Prior to index visit, history of TNFi use, n | 880 |
| 0 | 374 (42.5) |
| 1 | 341 (38.8) |
| 2+ | 165 (18.8) |
| Prior to index visit, history of non-TNFi use, n | 880 |
| 0 | 746 (84.8) |
| 1 | 94 (10.7) |
| 2+ | 40 (4.5) |
| Prior to index visit, history of tsDMARD (tofacitinib) use, n | 880 |
| 0 | 872 (99.1) |
| 1 | 8 (0.9) |
| Prior to index visit, history of bDMARD/tsDMARD use, n | 880 |
| 0 | 352 (40) |
| 1 | 311 (35.3) |
| 2 | 121 (13.8) |
| 3+ | 96 (10.9) |
| Current treatment reported at index visit, n | 880 |
| bDMARD/tsDMARD, n | 270 |
| TNFi | 197 (22.4) |
| Non-TNFi | 69 (7.8) |
| tsDMARD | 4 (0.5) |
| Not on bDMARD/tsDMARD | 610 (69.3) |
| Current prednisone use at index visit, n | 160 |
| < 5 mg | 42 (26.3) |
| ≥ 5 mg to ≤ 10 mg | 103 (64.4) |
| > 10 mg | 15 (9.4) |
Values are n (%) unless otherwise specified.
↵* Treatment reported at the visit prior to cancer diagnosis. Out of 880 patients, 734 patients had a visit within 12 months before the index date. The mean (SD) months from index date to the visit prior to cancer (solid tumor only) diagnosis is 8.4 (7.5) months. bDMARD: biological disease-modifying antirheumatic drug; TNFi: tumor necrosis factor inhibitor; tsDMARD: targeted synthetic DMARD; csDMARD: conventional synthetic DMARD; IQR: interquartile range.